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able for truncal obesity and no hepatosplenomegaly or vascular
bruits. He had intact sensation and motor function of all four
extremities as well as normal deep tendon reflexes.
Laboratory testing revealed a serum potassium of 4.8 mEq/L;
BUN, 26 mg/dL; serum creatinine, 1.9 mg/dL; hematocrit,
38.8%; serum cholesterol, 287 mg/dL; 24-hour urinary protein,
3.6 g; and a creatinine clearance of 52 mL/min. His serum
albumin was 2.2 g/dL. The urine sediment showed 0-2 red
blood cells/high-power field and hyaline casts. Serum protein
electrophoresis and urine protein electrophoresis did not reveal
paraproteins. Serologic evaluation for other causes of renal
dysfunction and proteinuria was negative.
The purpose of the consultation was to recommend the opti-
mal treatment strategy for treating the blood pressure and
proteinuria and for inhibiting his progressive renal disease.
CASE PRESENTATION
A 54-year-old white man was referred by his internist for DISCUSSION
evaluation of a serum creatinine of 1.9 mg/dL and nephrotic-
Dr. Matthew R. Weir (Head, Division of Nephrology,range proteinuria (3.6 g/24 h). The patient had an approximate
10-year history of non–insulin-dependent diabetes mellitus and and Director, Clinical Research Unit, Department of Med-
a 15-year history of hypertension. The patient also reported icine, University of Maryland School of Medicine, Balti-
that he had a history of a mildly enlarged heart and an elevated more, Maryland, USA): This case exemplifies the prob-
cholesterol level but denied previous visual abnormalities, lem that clinicians face in the management of patientschest pain, shortness of breath, or peripheral edema. He re-
with hypertension and early renal insufficiency. Whatported that he has always been stocky but had gained approxi-
is the best strategy for preventing progression of bothmately 10 pounds during the previous year. He stated that
atherosclerotic cardiovascular disease and chronic renalhis glucose levels were reasonably controlled between 130-200
mg/dL with diet and oral medication, but that his blood pres- failure? In my discussion, I will focus on the most rele-
sure was hard to treat and his physician had prescribed many vant issues in the management of this patient. Among
different medicines. these, I will review the concept of renal autoregulation
On physical examination, he was a middle-aged, overweight
because it provides a rationale for optimal levels of bloodwhite male who was 510” tall and weighed 230 pounds. His
pressure and for which medications might need to beblood pressure was 162/98 mm Hg and did not vary between
prescribed. An understanding of renal autoregulationarms or with position. Funduscopic examination revealed arte-
riolar narrowing, a rare microaneurysm, and two small hemor- also provides a framework for understanding (1) the
rhages in his left retina. His lungs were clear. Cardiovascular relationship between blood pressure and renal injury,
examination disclosed normal carotid upstrokes, a regular (2) the option of intensive control of blood pressure,
heart rate and rhythm, an S4 gallop, and 1 peripheral pulses
and (3) the particular role of drugs that block the renin-without pedal edema. His abdominal examination was remark-
angiotensin-aldosterone system (RAAS). I will conclude
with some comments about the importance of protein-
The Nephrology Forum is funded in part by grants from Amgen, uria as a prognostic and modifiable risk factor for cardio-
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- vascular and renal disease progression and why preventingrated; and Bristol-Myers Squibb Company.
renal failure is important for reducing the risk of cardio-
Key words: hypertension, proteinuria, cardiovascular risk. vascular events. These topics will provide a framework
for an understanding of the optimal therapeutic strategies 2002 by the International Society of Nephrology
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Fig. 1. Relationships among systemic, glomer-
ular capillary, and peritubular capillary pres-
sures. The glomeruli and peritubular capillar-
ies operate at lower pressures than systemic
pressure; consequently, adequate autoregula-
tion of blood flow must occur to “step down”
systemic pressure. Autoregulation is primarily
governed by either myogenic responses of the
afferent arteriole or by tubuloglomerular feed-
back mechanisms (stimulated by adenosine,
angiotensin II and renal sympathetic nerve
activity, and inhibited by nitric oxide). Failure
of autoregulation either due to myogenic re-
flex dysfunction secondary to vascular disease,
or tubuloglomerular feedback dysfunction
from diabetes due to excess nitric oxide pro-
duction may result in glomerular capillary hy-
pertension and injury.
for delaying progression of renal and cardiovascular dis- chanical injury to the delicate glomerular capillary ves-
sels. Should glomerular capillary perfusion fall below theease in the patient with incipient nephropathy.
autoregulatory threshold of approximately 60 mm Hg
Risk factors because of systemic hypotension, then increasing activa-
tion of the RAAS enhances efferent glomerular arterio-Multiple risk factors affect the development of cardio-
lar vasoconstriction and facilitates maintenance of glo-vascular disease and progression of renal disease in
merular capillary pressure in a range that is necessarypatients with early renal insufficiency. These include
for filtration [6].non-modifiable risk factors such as genetics, but more
Adequacy of control of glomerular capillary pressureimportant, they include modifiable risk factors such as
is likely one of the most important factors in reducingglycemic control, dietary protein and salt intake, blood
pressure, dyslipidemia, hyperhomocystinemia, protein- risk for progression of renal injury (Fig. 1). Control of
uria, and cigarette smoking [1–3]. For the sake of clarity glomerular capillary pressure works well within the nor-
and brevity, I will focus here on factors related to blood mal autoregulatory range of the kidney (60-150 mm Hg)
pressure and proteinuria both as interdependent and [4–7]. Patients with pressures exceeding 150 mm Hg, or
independent modifiable risk factors for progression of patients with damage to the autoregulation capacity of
renal insufficiency and ultimately cardiovascular disease. the afferent glomerular arterioles (as can occur in a pa-
tient with diabetes and vascular disease or who ingests
Renal autoregulation a high-protein diet) can be vulnerable to injury from
levels of systemic blood pressure within the so-calledRenal autoregulation is the physiologic mechanism
whereby glomerular capillary pressure varies by only “normotensive” range (125-140 mm Hg). This level of
blood pressure exceeds the usual range of pressures inabout 5 mm Hg over a wide range (60 to 150 mm Hg)
of alterations in the renal perfusion pressure. Increasing the glomeruli and therefore can cause glomerular capil-
lary hypertension in patients with damaged autoregula-systemic blood pressure induces a myogenic reflex that
stimulates smooth muscle cells in the afferent glomerular tory capacity. These circumstances, coupled with the in-
creased vasodilation of the afferent glomerular arteriolearterioles to initiate a reflex contraction that reduces
renal blood flow [4]. A second mechanism that facilitates in diabetes mellitus [8], markedly increase glomerular
capillary pressure and the risk for injury. The increasingpreglomerular vasoconstriction is the increased delivery
of sodium chloride to the distal nephron, which stimu- pressure can result in mechanical stretch and strain
within the delicate glomerular capillary vascular bedslates a tubuloglomerular feedback mechanism that causes
afferent arteriolar vasoconstriction [4, 5]. As a conse- and mesangial cells; this stress in turn results in an injury
and repair response largely mediated by fibrogenic cyto-quence of these two mechanisms, autoregulation of glo-
merular capillary pressure is carefully maintained within kines and angiotensin II [9]. Repetitive injury results
in scarring, inflammation, and glomerulosclerosis anda tight range, thereby assuring stable glomerular filtra-
tion while simultaneously reducing the likelihood of me- ultimately leads to loss of renal function. Subsequent loss
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The Modification of Diet in Renal Disease (MDRD)
study demonstrated important benefits of rigorous con-
trol of blood pressure in patients with non-diabetic renal
disease and proteinuria (Fig. 2) [11, 15]. The proteinuric
patients (defined as patients with 1 g of proteinuria/
day) demonstrated substantial benefits with better blood
pressure control (125/75 mm Hg), perhaps because the
proteinuria was a reflection, in part, of impaired renal
autoregulation and glomerular capillary hypertension.
Bakris demonstrated a nearly linear relationship be-
tween systolic blood pressure achieved with pharmaco-
therapy and rate of loss of renal function each year in an
evaluation of non-diabetic patients and diabetic patients,
both groups with renal disease [16]. Likewise, Jafar et
al noted an increased risk for doubling of serum creati-
nine or reaching end-stage renal disease in a meta-an-
alysis of patients with non-diabetic renal disease as a
function of systolic blood pressure achieved with phar-
macotherapy [17]. These and other clinical observations
have provided important insights for establishing goals
for optimal levels of blood pressure in patients with renal
disease.
These analyses also have indicated that an average of
3 to 4 medications (or more) are needed to achieve lower,
more intensive blood pressure control (125-130 mm Hg
systolic) in patients with renal disease. However, these
studies have not provided insight as to how early in the
Fig. 2. Mean decline in GFR (mL/min) over a 36-month period in course of renal failure one should intensify treatment so
groups with four different mean baseline 24-hour urine protein levels as to optimally prevent progressive renal injury. As I
in non-diabetic patients with chronic renal failure in the MDRD study
will discuss in a moment, several clinical trials in diabetes[15]. Compared in each of these four groups are the normal blood
pressure group (dashed line; 140/90 mm Hg; 102-107 mm Hg MAP) indicate that the earlier the intervention, preferably in
and the intensive control group (solid line; 125/75 mm Hg; 92 mm Hg the so-called “pre-hypertensive stage” (blood pressure
MAP).
less than 130/80 mm Hg), the greater the likelihood of
preventing progressive renal injury (as a reflection of
preventing progression from microalbuminuria to clini-
cal proteinuria). Needless to say, blood pressure is moreof nephrons results in the development of glomerular
capillary hypertension in residual nephron units, conse- easily controlled with less medication when the untreated
systolic blood pressure is 130-140 mm Hg. Possibly, ear-quently exposing them to further mechanical injury [10].
This series of sequential events ultimately leads to pro- lier treatment will prevent the need for more medication
in subsequent years. This hypothesis is an importantgressive renal insufficiency. Consequently, patients with
incipient nephropathy might require levels of systemic consideration that needs to be tested in clinical trials.
blood pressure below what we have traditionally targeted
Proteinuria and renal injuryin order to reduce the risk for progressive renal injury.
Evidence from clinical trials indicates that proteinuria
Blood pressure and renal injury is an independent predictor of progression of renal dis-
ease [15, 18, 19]. The severity of baseline proteinuria isThe kidney’s ability to regulate glomerular pressure
is important for prevention of renal injury. Rigorous an important predictor, not only of the rate, but also of
the likelihood, of loss of renal function [15, 17]. Clinicalcontrol of both systemic and glomerular capillary blood
pressure is needed, particularly in patients with certain trials also have demonstrated that the reduction in pro-
tein excretion with antihypertensive agents or dietarydiseases, such as diabetes, that can predispose to im-
paired renal autoregulation. Abundant clinical data indi- protein restriction correlates directly with the reduction
of the rate of loss of renal function [20, 21]. Newer clinicalcate that the net level of blood pressure achieved with
antihypertensive therapy is predictive of risk for losing trials indicate that the net reduction in proteinuria
achieved with antihypertensive therapy ultimately pre-renal function both in non-diabetic patients and diabetic
patients with renal disease [11–14]. dicts the rate of loss of renal function over time; the
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Fig. 3. Final common pathway whereby pro-
teinuria results in the development of glomeru-
losclerosis and fibrosis [Adapted from Ref. 26].
initial severity of baseline proteinuria does not [19, 22]. as it results in increased glomerular permeability to pro-
teins and, at the same time, greater mechanical stretchThese observations indicate that proteinuria is a modifi-
able risk factor of progressive renal disease. However, and strain within the glomeruli and surrounding mesan-
gial cells. This process results in greater production ofin clinical practice, attempting to reduce or abolish pro-
teinuria is not common, as more emphasis has been angiotensin II, transforming growth factor-1, and a sub-
sequent increase in collagen synthesis [9, 26]. Conse-placed on reducing blood pressure.
Microalbuminuria is an important predictor of subse- quently, both glomerular hyperfiltration and excessive
tubular reabsorption of proteins are likely additionalquent risk for nephropathy in both type 1 and type 2
diabetes [23–25]. Its presence also is predictive of cardio- causes of renal injury.
The reduction of proteinuria is important in patientsvascular mortality in diabetic and non-diabetic patients
[23–25]. Microalbuminuria likely reflects evidence of a both with non-diabetic and diabetic renal disease. The
Ramipril Efficacy in Nephropathy (REIN) study was insystemic vasculopathy, with damage to the glomerular
vascular bed being one of the first areas of damage that part designed to assess the relationship between protein-
uria and progression of renal disease in non-diabeticis clinically evident. Microalbuminuria also can represent
evidence of glomerular capillary hypertension and hyp- patients. Investigators noted that the mean rate in de-
cline in GFR of the patients whose urinary protein excre-erfiltration, perhaps due to loss of afferent glomerular
arteriolar vasoconstriction and dysfunctional autoregula- tion was between 1 and 3 g/day was one-third that of
the patients whose urinary protein excretion was greatertion of glomerular capillary blood pressure. Thus, the
presence of microalbuminuria, like proteinuria, indicates than 3 g/day [18]. Moreover, this study also noted that
the use of the ACE inhibitor ramipril was the only time-the patient with a greater risk of developing both pro-
gression of renal disease and cardiovascular events. dependent variable that predicted the slower rate in de-
cline of GFR. The report thus concluded that renal pro-Excessive proteins filtered by the glomerulus lead to
an increase in both renal tubular cell reabsorption of tection was linked to a reduction in urinary protein excre-
tion and not blood pressure.proteins and overall protein catabolism. Remuzzi and
Bertani have suggested that excessive renal tubular cell Jafar et al conducted a meta-analysis of 1860 patients
enrolled in 11 randomized controlled trials comparingreabsorption of proteins activates vasoactive and in-
flammatory genes, thereby resulting in the synthesis and the effects of multidrug antihypertensive regimens, inclu-
ding or not including ACE inhibitors, on the progressionelaboration of several substances within the interstitium.
These substances in turn result in fibrogenesis, collagen of non-diabetic renal disease [17]. They demonstrated
that the level of proteinuria achieved with pharmacother-production, and scarring (Fig. 3) [26]. Glomerular capil-
lary hypertension would likely accelerate this process, apy was predictive of the rate of loss of renal function.
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This finding indicated that urinary protein excretion was These results are in concert with the observation by
the Collaborative Study Group of the advantages of thea modifiable risk factor for the progression of renal dis-
ease. It is interesting that they also noted that the benefi- ACE inhibitor captopril versus conventional therapy in
preventing renal insufficiency in type-1 diabetes [27].cial effect of ACE inhibitors in retarding progression
of renal disease remained significant, even after they However, similar conclusive data showing nephroprotec-
tion are not available with ACE inhibitors in proteinuriccontrolled for the level of urinary protein excretion
achieved. type 2 diabetic patients with incipient nephropathy.
Two placebo-controlled studies indicated that ACEThe Collaborative Study Group demonstrated that
only patients with type 1 diabetes who achieved at least inhibitors could prevent the progression of microalbu-
minuria to macroproteinuria in “normotensive” (systolica 50% reduction in urinary protein excretion derived
benefit, defined as subsequent stabilization of renal func- 125-130 mm Hg) type-1 and type-2 diabetic patients
[35, 36]. In both studies, modest but significant reductionstion [27]. This study indicated that intensive antiprotein-
uric strategy, concurrent with an optimal blood pressure in blood pressure occurred with ACE inhibitor therapy.
Consequently, one cannot be sure whether the preven-strategy, is important in reducing the likelihood of pro-
gressive nephropathy in type 1 diabetics. Information tion of macroproteinuria is simply a blood pressure ef-
fect, a unique effect of the ACE inhibitor, or both. Theseregarding the importance of reducing proteinuria on the
rate of progression of renal disease in patients with type-2 studies also indicated that earlier therapeutic interven-
tion, even with treatment of blood pressure in the “nor-diabetes is inconsistent, in large part because of the small
size and short duration of the studies to date (abstract; motensive” range, could prevent the development of
macroproteinuria.Walker et al, J Am Soc Nephrol 3:339, 1992) [28–32].
With the completion of the Irbesartan Diabetic Ne- In the Heart Outcomes Prevention Evaluation (HOPE)
trial, patients with cardiovascular disease, type 2 diabe-phropathy Trial (IDNT) and the Reduction of Endpoints
in NIDDM with the Angiotensin II type-1 Antagonist tes, or both demonstrated important cardiovascular risk
reduction when blood pressure was reduced below aLosartan (RENAAL) trial [33, 34], more information is
now available to correlate the importance of reduction traditionally acceptable level of 139/79 mm Hg by adding
the ACE inhibitor ramipril, 10 mg/day, to the medicalin proteinuria on renal outcomes in patients with type-2
diabetes and incipient nephropathy. Although not com- regimen [37]. Thus, earlier and more intensive efforts to
control blood pressure with ACE inhibitors can havepletely analyzed yet, both studies likely will show a direct
correlation between the antiproteinuric effects of the important cardiovascular benefits in patients with type
2 diabetes.angiotensin II receptor blocker and protection of renal
function. Six studies have compared ACE inhibitor versus non-
ACE-inhibitor therapy in proteinuric patients with type
Implications of lower blood pressure goals and 2 diabetes with two to five years of follow-up (abstract;
proteinuria on antihypertensive medication selection Walker et al, J Am Soc Nephrol 3:339, 1992) [28–32].
Unfortunately, there are fewer than 400 patients in all sixLower blood pressure goals in the presence of micro-
albuminuria or proteinuria are important considerations studies combined. Only one of these six studies showed
significant differences between the decline in GFR infor treatment. Reaching the desired systolic blood pres-
sure goal frequently requires one drug for every 10 patients treated with or without ACE inhibitors [28].
Thus, one can only extrapolate the benefits of an ACEmm Hg of systolic blood pressure reduction. The pres-
ence of microalbuminuria or proteinuria requires specific inhibitor in proteinuric patients with type 2 diabetes
based on experience in type 1 diabetic patients or pa-therapy including drugs that block the renin-angiotensin
system, non-dihydropyridine calcium channel blockers, tients with non-diabetic renal disease.
Whether the benefits of ACE inhibitors in preventingand restriction of dietary sodium and protein. Protein-
uria and hypertension are separate and independent yet or protecting against worsening of renal disease can be
generalized to other classes of drugs that block the renin-intertwined modifiable risk factors for progression of
renal insufficiency. angiotensin system can now be addressed with the results
of two recently completed trials. The RENAAL andAngiotensin-converting-enzyme (ACE) inhibitors at-
tenuate the rate of progression of renal disease both in IDNT trials provide evidence that an angiotensin II
type-1 receptor blocker protects against the progressiontype 1 diabetics [13, 26] and patients with non-diabetic
renal disease [17]. The benefit of ACE inhibitors likely of renal disease in type 2 diabetics, independent of blood
pressure effects [33, 34]. Both these studies demonstratedis derived from antihypertensive/antiproteinuric proper-
ties and the anti-mitogenic/anti-fibrogenic effects of an- statistically significant risk reduction for doubling of se-
rum creatinine, end-stage renal disease (ESRD), andgiotensin II antagonism [9]. The meta-analysis by Jafar
et al demonstrated the important benefit of ACE inhibi- death (the primary composite end point of the trials)
compared to traditional (diuretic, beta blocker, vasodila-tors in patients with non-diabetic renal disease [17].
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Fig. 4. Annual cardiovascular disease mortality for the general population (GP) and dialysis population based on gender, race, and age. The data
were generated from the National Center for Health Statistics (1993) and from the United States Renal Data System Report of 1994-1996 [41].
tor, etc.) or calcium channel blocker-based therapy. progressive renal failure have not been performed. How-
ever, if their benefits are tied primarily to blood pressureMoreover, both studies demonstrated a consistent anti-
proteinuric effect of the angiotensin II type-1 receptor and proteinuria reduction, then it is likely that the two
classes of drugs would be similar given their similar effi-blocker. Although not analyzed yet, it is likely that, as
in the study with captopril in type-1 diabetics [27], the cacy in short-term clinical trials.
The clinical data with drugs that block the renin-angio-anti-proteinuric effect of the angiotensin II receptor
blockers losartan (RENAAL) and irbesartan (IDNT) tensin system support the pathophysiologic construct
linking glomerular capillary hypertension, proteinuria,will correlate with their nephroprotective properties. The
Irbesartan Microalbuminuria Trial (IRMA-2), which was and risk for progression of renal disease [10]. It is not
known whether an ACE inhibitor and an angiotensin IIconducted in hypertensive microalbuminuric patients
with type-2 diabetes, demonstrated that an angiotensin type-1 receptor blocker given together provide greater
protection against progressive loss of renal function thanII type-1 receptor blocker could prevent the develop-
ment of clinical proteinuria when compared with tradi- administration of either agent alone. Some clinical stud-
ies indicate that an ACE inhibitor and angiotensin IItional antihypertensive therapy, despite similar reduc-
tions in blood pressure [38]. type-1 receptor blocker together provide more effective
blood pressure reduction [39] and near additive anti-As a result of these newer trials, it appears that ACE
inhibitors as well as angiotensin II type-1 receptor block- proteinuric effects [40].
ers retard progression of renal disease compared with
Relationship between renal disease progression andother therapies. The evidence supporting ACE inhibitors
cardiovascular diseaseis in patients with type-1 diabetes and non-diabetic renal
disease, while the evidence supporting the use of the Preventing progression of renal disease is an important
strategy in reducing the risk for cardiovascular events.angiotensin II type-1 receptor blockers is in patients with
type-2 diabetes. The rationale supporting the use of these Patients with renal insufficiency, especially those with
ESRD, have a markedly increased risk for cardiovasculardrugs relates in part to their more consistent antihyper-
tensive and antiproteinuric effects relative to other anti- events (Fig. 4) [41]. This cardiovascular risk is especially
substantial in diabetics, who also have a higher mortalityhypertensive drugs. In addition, antihypertensive- and
anti-proteinuric-independent benefits are likely associ- rate if they are on dialysis or have had a transplant
[42, 43]. In the IDNT trial, nearly 25% of the type-2ated with these therapies [17]. Clinical trials comparing
the two therapies with regard to reducing the risk of diabetic patients had a doubling of the serum creatinine.
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Of those patients with doubled serum creatinine, 50% Dr. Madias: Despite reaching target blood pressure,
many patients with renal disease continue to have sig-underwent dialysis within one year, and 25% were dead
within three years. Consequently, any strategy that is nificant proteinuria. Could you comment on additional
strategies for controlling proteinuria, such as usingeffective in preventing a doubling of serum creatinine
also will likely be beneficial in reducing the risk of cardio- “mega doses” of ACE inhibitors, combining ACE inhibi-
tors with angiotensin II type 1 receptor antagonists, andvascular events.
the use of aldosterone antagonists?
Summary Dr. Weir: The use of large or “mega” doses of ACE
inhibitors is a fascinating area. In general, clinicians,Let me summarize. I argue that optimal strategies to
provide more effective prevention or protection against and even many nephrologists, are concerned about using
higher doses of ACE inhibitors, even doses in the ap-renal disease progression should focus on earlier and
more intensive blood pressure reduction, proteinuria re- proved dosing range, let alone “mega” doses. This is
particularly true in patients who have early evidence ofduction (preferably eliminated), and renin-angiotensin-
aldosterone system pharmacologic blockade. These are renal disease (serum creatinine, 1.4-2.0 mg/dL) despite
demonstrated efficacy and safety of these drugs in clinicalmodifiable risk factors for development of progressive
renal insufficiency. I believe that the weight of medical trials. Small studies have shown that titrating ACE inhib-
itors to higher doses can effectively reduce proteinuriaevidence supports the need for earlier and more intensive
efforts to control blood pressure below traditionally ac- [44]. This is also a function of higher doses providing
more effective reduction in blood pressure. Adding anceptable levels (less than 130/80 mm Hg), particularly if
evidence of microalbuminuria or proteinuria is present. angiotensin II receptor blocker, thiazide diuretics, or a
non-dihydropyridine calcium antagonist also can some-We need to identify patients at risk earlier, use a rela-
tively large number of drugs to achieve our goals, and times potentiate the antiproteinuric effects of ACE in-
hibitors. Several small clinical trials have indicated thebetter educate the public and clinicians of the need for
earlier, more rigorous efforts for the control of all risk benefit of this strategy (abstract; Hemmelder et al, J Am
Soc Nephrol 6:420, 1995) [40, 45]. Again, how muchfactors. Efforts at encouraging a healthier lifestyle by
reducing smoking, reducing a high-salt and high-satu- the further reduction in blood pressure plays a role in
decreasing proteinuria remains open to question. Alsorated-fat diet, and by increasing the frequency of exercise
can help reduce cardiovascular risk and improve the not resolved is the mechanism of incremental reduction
of proteinuria: are there specific effects on the glomeru-efficacy of antihypertensive, antiproteinuric medications.
lar basement membrane, or are the additive effects of
QUESTIONS AND ANSWERS these specific drugs purely related to reducing systemic
and glomerular capillary pressure?Dr. Nicolaos E. Madias (Executive Academic Dean,
Tufts University School of Medicine, Boston, Massachu- Perhaps more demanding of our attention is the clini-
cal importance of modifying dietary salt consumption.setts): You indicated that for certain groups with renal
disease, a lower target for blood pressure control might The scientific literature clearly indicates that the antipro-
teinuric and antihypertensive effects of all drugs are com-apply, that is, lower might be better than low. Could
you give us more specific recommendations about target promised by increasing dietary salt consumption (even
in the physiologic range) [46–48]. Consequently, effortsblood pressures for a range of groups within the renal
disease population? at modifying salt consumption should always be part of
every antiproteinuric strategy. Whether adding a thia-Dr. Weir: I can give you some of my own thoughts,
but I can’t back them up with any data, because clinical zide diuretic, or another drug like an angiotensin II re-
ceptor blocker, or using higher doses of ACE inhibitorstrials have not been completed that pursued either sys-
tolic blood pressure below 125 mm Hg or specific treat- or angiotensin II receptor blockers would render the
patient more tolerant to the hypertensive and proteinuricment for extinguishing proteinuria or albuminuria. With
regard to the patient with chronic renal insufficiency effects of higher dietary salt intake needs to be tested in
clinical trials. Perhaps this is another reason why higherwith either the presence of micro- or macroalbuminuria/
proteinuria, my clinical efforts are geared toward at least doses of ACE inhibitors and angiotensin II receptor
blockers (in the approved dosing range, or possiblygetting the systolic pressure into the 120s and extinguish-
ing the proteinuria or albuminuria. If I am unsuccessful in above) need to be considered in clinical practice as part
of a strategy for facilitating better reduction in bothattaining those two goals, then I continue to add specific
mediations to further lower the systolic pressure and blood pressure and proteinuria. Modifying dietary pro-
tein intake also might help reduce proteinuria, but itextinguish the proteinuria, much in the same way that
a cardiologist would advance ACE inhibition to reach raises concern about adequacy of nutrition and requires
expert nutritional counseling.doses demonstrated to be effective in the risk reduction
trials in heart failure. Another area of interest is the pharmacologic block-
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ade of aldosterone. Some small clinical studies indicate progression of vascular disease. Large-scale clinical tri-
als, such as the Heart Outcomes Prevention Evaluationthat aldosterone blockade and ACE inhibition have ad-
ditive antiproteinuric effects (abstract; Epstein et al, Am (HOPE), have shown unequivocal benefit of lower blood
pressure and blocking the RAAS [37]. Other clinicalJ Coll Cardiol 39(Suppl 4): 249A, 2002). This information
needs to be substantiated in future clinical trials. trials in patients with cardiac or renal disease demon-
strated similar, consistent benefits with better blood pres-Dr. Madias: Although we have been using ACE inhib-
itors for many years, it might well be that we are far sure control and blocking of the RAAS [37, 49].
Dr. James Strom (Division of Nephrology, St. Eliza-from knowing how to use them optimally. We tend to
use virtually the same doses for a very wide range of clin- beth’s Medical Center, Brighton, MA): One of the con-
founding features of the evaluation of proteinuria in anical settings—asymptomatic hypertension, hypertension
with left-ventricular hypertrophy, congestive heart fail- individual is the potential for “structural” protein loss.
We all follow patients with class-IV lupus nephritis inure, diabetic microalbuminuria, overt diabetic nephropa-
thy, and advanced renal disease. We might find that whom one doesn’t really believe the proteinuria is due
to hyperfiltration. Patients like this might have a combi-widely different doses of ACE inhibitors are required
for optimal response in various clinical settings. nation of factors causing heavy proteinuria despite con-
trolled systolic pressure. How would you advise proceed-Dr. Weir: Your point is excellent. All the dosing
ranges have been driven by clinical trials focusing on ing in such a situation?
Dr. Weir: Your question raises the issues of the rela-blood pressure reduction. There might be other clinical
disease states that require different dosing strategies. As tive contribution of glomerular capillary pressure eleva-
tion and glomerular structural injury to proteinuria, andI mentioned earlier, in patients with systolic heart failure,
higher doses of ACE inhibitors than necessary to im- the most effective way to treat it. I would submit that
the lower the glomerular capillary pressure, the less theprove circulatory hemodynamics have demonstrated re-
ductions in cardiovascular morbidity and mortality [49]. hydraulic force of transglomerular passage of proteins.
In a patient with glomerulonephritis and nephrotic-rangeDr. John T. Harrington (Dean, Tufts University
School of Medicine): What’s the evidence in humans proteinuria, I would employ more rigorous efforts to
drive that systolic blood pressure down as low as comfort-that proteinuria means an abnormality in glomerular
capillary pressure regulation? Second, how much of the ably possible (to avoid presyncope) with drugs that block
the RAAS.effect of angiotensin II blockade is hemodynamic, and
how much is a nonhemodynamic effect? Dr. Allon Friedman (Renal Fellow, Division of Ne-
phrology, New England Medical Center, Boston, MA):Dr. Weir: Those two questions are excellent. I am not
sure that microalbuminuria, in and of itself, indicates You spoke about how we can use proteinuria as a surro-
gate marker to titrate blood pressure to ideal levels.the presence of glomerular capillary hypertension. I am
suspicious that it indicates either vasculopathy, inade- However, some of our clinic patients who have chronic
renal disease do not exhibit proteinuria. What surrogatequate renal autoregulation, or possibly both. How to
quantify the contribution of each for a given patient is markers would you use with these patients?
Dr. Weir: We clearly need more effective means ofnot yet known. I mention this to alert the clinician that
the presence of microalbuminuria suggests a need for determining which patients with renal disease are at risk
for developing progressive renal disease and cardiovas-better blood pressure control (to less than 130 mm Hg
systolic) and a therapeutic strategy designed to extin- cular disease, particularly if they have minimal evidence
of proteinuria. The NIDDK has just started an observa-guish the microalbuminuria.
One important consideration as part of a therapeutic tional cohort study in patients with early renal insuffi-
ciency to look at biomarkers for progression of bothstrategy is blocking the activity of the RAAS. How is
the RAAS involved in the development of vascular dis- renal and cardiovascular disease. When completed, this
trial should provide much relevant information. Our cen-ease? On one hand, the RAAS is well described as a
neuroendocrine system that regulates circulatory ho- ter is evaluating different therapeutic strategies in renal
transplant recipients with biopsy-proven chronic allo-meostasis. But the RAAS also might have effector func-
tion in an autocrine or paracrine fashion by regulating graft nephropathy and low-grade proteinuria to deter-
mine the optimal level of blood pressure and specificvascular injury and repair responses, ultimately leading
to remodeling and restructuring. From a clinical stand- benefits of drugs that block the RAAS. This study pro-
vides measurements of renal function and renal histologypoint, there is an interrelationship between level of blood
pressure with the resulting mechanical stretch and strain, with sequential renal biopsies during follow-up. The ob-
servations of this study also might provide importantvascular risk factors, and progression of vascular injury.
These observations might explain why rigorous control insights into the management of patients with other
forms of renal disease.of blood pressure coupled with therapeutic strategies
that block the RAAS have more success in slowing the Clinical trials to evaluate optimal strategies in patients
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with non-proteinuric renal disease will likely take longer inhibitor–based multidrug regimen demonstrated a pow-
erful impact on reducing cardiovascular events [50].and require larger numbers of patients to demonstrate
statistically significant benefits in reducing end points. Dr. Madias: You mentioned a number of interesting
hypothetical trials. Do you want to use this Forum toThe MDRD trial demonstrates this point nicely. In the
meantime, patients with renal disease, even those with specifically delineate two or three of those that you think
are the most pressing in our field?minimal proteinuria, should still have rigorous efforts to
control systolic blood pressure below 130 mm Hg, and Dr. Weir: There is a substantial variation in physician
use of drugs that block the RAAS in patients withpreferably with drugs that block the RAAS.
Dr. Katrin Uhlig (Renal Fellow, Division of Nephrol- chronic renal failure or end-stage renal disease despite
the overwhelming evidence of increased cardiovascularogy, New England Medical Center): At the ASN meeting,
Dr. Andrew Levey showed data from further analysis disease in these patients. Perhaps doctors are concerned
about changes in creatinine or potassium, or the per-of the AIPRD (Angiotensin Converting Enzyme Inhibi-
tion in Progressive Renal Disease) study. These data ceived lack of need of these drugs after the kidneys
have failed. For that reason, a clinical trial is needed toshowed that the beneficial ACE-inhibitor effect was only
partially explained by lowering of both blood pressure evaluate the benefit of drugs that block the RAAS on
cardiovascular end points in patients with establishedand proteinuria (abstract; Jafar J, Am Soc Nephrol
11:A0345, 2000). Could you comment on that? Also, renal disease or end-stage renal disease. Two outcome
trials have been organized at our center to evaluate thedo any data suggest that ACE inhibitors or angiotensin
receptor blockers work in different ways in diabetic ver- benefits of ACE inhibitors and angiotensin II receptor
blockers in patients on dialysis or who have received asus nondiabetic renal disease?
Dr. Weir: It is likely that drugs that block the RAAS— renal transplant. Patients will receive similarly effective
pharmacotherapies to control blood pressure. The differ-the ACE inhibitors and angiotensin II receptor block-
ers—have blood pressure-dependent and blood pres- ence in outcome for patients on a drug that blocks the
RAAS versus a non-RAAS-blocking drug will be com-sure-independent benefits on slowing progression of
renal disease in diabetics and non-diabetics. It will proba- pared on cardiovascular end points. As part of our efforts
to design these two trials, we are also evaluating physi-bly take more patients or longer follow-up to demon-
strate this in a single clinical trial, unless a properly cian use of drugs that block the RAAS in dialysis and
transplant patients. There are some surprising differ-performed meta-analysis of many clinical trials is done.
We still do not know with certainty the mechanism of ences among health care providers. In general, the usage
is quite low, particularly in patients with renal trans-action of either the ACE inhibitors or the angiotensin
II receptor blockers. Until we do, it is hard to predict plants.
Dr. John Gill (Research Fellow, Division of Nephrol-the long-term effects of these two therapeutic classes
that block the RAAS. ogy, New England Medical Center): In your previous
comments, you alluded to the transplant population onDr. Madias: We’re increasingly learning about the
cluster of genes that importantly influence susceptibility a couple of occasions. You suggested that we ignore the
potential benefits of angiotensin II receptor antagoniststo various chronic diseases. Could you talk about the
genetic background of the individual in terms of the rate compared to ACE inhibitors. However, given the poten-
tial for complications, specifically hyperkalemia, if weof progression of renal disease and the response to ACE
inhibition? decide to use these medications, might angiotensin II
receptor blockers be favored given their known abilityDr. Weir: I have not been overwhelmed with the avail-
able gene polymorphism data, particularly for the ACE to decrease TGF-?
Dr. Weir: Good point. Whether ACE inhibitors orgene, to make them clinically relevant at the present
time. This is particularly true in patients with nephropa- angiotensin II blockers can more effectively reduce renal
scarring, perhaps due to effects on angiotensin II orthy due to type 2 diabetes, the most common clinical
form of renal disease. TGF-, is unknown. Perhaps our current renal biopsy
study in transplant patients will shed light on this subject.Dr. Harrington: Nick asked you earlier about the
efficacy of the new aldosterone antagonists. Could you The potassium issue is an important one, as it frequently
is a stumbling block for physicians who want to prescribetell us more about it?
Dr. Weir: Eplerenone is a new selective aldosterone ACE inhibitors or angiotensin II receptor blockers.
These drugs do raise serum potassium on average 0.3 toreceptor antagonist that does not have the endocrine
side effects of spironolactone. Thus, it might allow the 0.5 mEq/L because of inhibition of aldosterone. One of
the intriguing questions is whether it is healthier for youstudy of higher doses of the drug to evaluate effects not
just on blood pressure, but also on vascular and target to have a potassium level of 5.5 to 6.0 mEq/L. That
might be a more desirable potassium level in people withorgan function. One congestive heart failure study that
utilized 12.5 to 25 mg of spironolactone with an ACE- cardiovascular risk factors. This possibility needs to be
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teinuria, and the progression of renal disease. The Modificationcarefully explored in large data bases. If you look at the
of Diet in Renal Disease Study. Ann Intern Med 123:754–762, 1995
wealth of information from clinical trials in congestive 16. Bakris GL: Maximizing cardio-renal benefits: Achieving blood
pressure goals. J Clin Hypertens 1:141–148, 1999heart failure or chronic renal insufficiency, the need for
17. Jafar TH, Schmid CH, Landa M: Angiotensin-converting enzymestopping an ACE inhibitor because of a potassium level
inhibitors and progression of nondiabetic renal disease. A meta-
of 6.0 mEq/L or greater occurs in less than 2% of pa- analysis of patient-level data. Ann Intern Med 135:73–87, 2001
18. The GISEN Group: Randomized placebo-controlled trial of effecttients. Thus, this is an infrequent clinical problem. It
of ramipril on decline in glomerular filtration rate of terminal renalcan largely be minimized if physicians ensure that their
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